首页> 外国专利> It makes the ranitidine or more which are chosen from the production mannered null magnesium hydroxide

It makes the ranitidine or more which are chosen from the production mannered null magnesium hydroxide

机译:它可以使雷尼替丁或更多的雷尼替丁选自生产纯净的氢氧化镁

摘要

PROBLEM TO BE SOLVED: To provide a solid pharmaceutical formulation containing ranitidine that controls discoloration of the ranitidine, and a method for producing a ranitidine-supporting particle to be blended with the formulation.;SOLUTION: The solid pharmaceutical formulation containing ranitidine is characterized in that it has acid-controlling power larger than 200 mL which is determined by the acid-controlling power testing method according to the fifteenth Revision of Japanese Pharmacopoeia and that it contains the ranitidine-supporting particle which supports the ranitidine on an inorganic compound containing magnesium and/or calcium having a magnesium and/or calcium content of 20 mass% or higher.;COPYRIGHT: (C)2010,JPO&INPIT
机译:解决的问题:提供一种包含雷尼替丁的固体药物制剂,该固体药物制剂控制雷尼替丁的变色,以及制备与该制剂混合的雷尼替丁支撑颗粒的方法。解决方案:包含雷尼替丁的固体药物制剂的特征在于:它具有大于200 mL的酸控制能力,该酸控制能力是根据日本药典第15次修订版通过酸控制能力测试方法确定的,并且含有雷尼替丁支持颗粒,该颗粒可将雷尼替丁负载在含有镁和/的无机化合物上或镁和/或钙含量为20质量%或更高的钙。版权所有:(C)2010,JPO&INPIT

著录项

  • 公开/公告号JP5560701B2

    专利类型

  • 公开/公告日2014-07-30

    原文格式PDF

  • 申请/专利权人 ライオン株式会社;

    申请/专利号JP20090292765

  • 发明设计人 尾谷 明希;石川 聡之;

    申请日2009-12-24

  • 分类号A61K31/341;A61K9/20;A61K47/04;A61P43/00;A61P1/04;C07D307/52;

  • 国家 JP

  • 入库时间 2022-08-21 16:13:55

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号